The cancer tissue page shows antibody staining in 20 different cancers. The overall cancer tissue staining statistics shows the fraction of patient samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right), using all the available antibodies to the protein targets encoded by this gene. The assay and annotation is described here.
The cancers can be ordered histologically or alphabetically.
For each cancer, the staining for each available antibody is reported as the fraction of samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right). The lenght of the bar represents the number of patient samples analysed (max=12 patients). By clicking on a cancer tissue, the detailed staining data for that cancer is available, including annotated images.
At the bottom of this page, a summary for the cancer staining for each antibody is given, together with the immunohistochemistry validation score for that antibody.
Strong nuclear staining in squamous cell carcinomas, while lymphomas, melanomas, testis- and prostate cancers displayed mostly negative or weakly stained cases. The quantity of positive cells was rarely more than 50% and sometimes the staining pattern varied considerable from case to case. Hepatocellular carcinomas were generally negative in contrast to most cholangio carcinomas where positivity was registered.
Strong nuclear staining in most cervical, urothelial, stomach, pancreatic and skin cancers. Negative or weak staining in prostate, lung, skin and testis cancers. Malignant carcinoids, gliomas and lymphomas were also mainly negative.
Validation
Two (or more) antibodies yielding similar staining patterns which are consistent with available gene/protein characterization data
Two (or more) antibodies yielding similar staining patterns which are consistent with available gene/protein characterization data
